Follow breast-screening guidelines for transgender females with no increased risk
STEP 1 — Gather Information
Collect patient gender identity, current age, duration and type of gender-affirming hormone therapy (estrogen ± anti-androgen), personal and family history of breast cancer, known genetic mutations (e.g., BRCA), prior chest radiation, and any prior breast surgery or mastectomy to determine baseline risk status.
STEP 2 — Rule In / Rule Out
If the patient is a transgender female and has been assessed as having no known increased risk of breast cancer (no personal/family history, no BRCA, no chest radiation, etc.), proceed to step 3; otherwise, follow high‑risk breast‑cancer screening pathways.
STEP 3 — Classify or Stratify
Stratify by age using average‑risk guidelines for cisgender females: ages 40‑49 (consider shared decision‑making for annual mammography), 50‑74 (biennial mammography), 75+ (continue if life expectancy ≥10 years). Adjust for hormone‑therapy‑induced breast density if needed but do not change interval.
STEP 4 — Decide
Recommend screening mammography according to the age‑based interval determined in step 3; if breast tissue is absent (e.g., after total mastectomy), discontinue routine screening and follow post‑mastectomy surveillance.
Clinical Guardrails / Mimics / Pitfalls
Do not withhold screening because of hormone therapy; do not apply male breast‑cancer guidelines; do not delay screening due to concerns about feminization; recognize that estrogen therapy may increase breast density but does not alter recommended screening interval; if a mastectomy has been performed, follow post‑mastectomy guidelines instead of average‑risk screening.
Concrete Clinical Example
A 52‑year‑old transgender female on estradiol 4 mg daily for 3 years reports no personal or family history of breast cancer, no BRCA mutation, and no prior chest radiation; she is assessed as no increased risk. Following step 3, she falls in the 50‑74 age bracket, so step 4 recommends biennial screening mammography.
Source: Endocrine Society Clinical Practice Guideline: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons, Wylie C. Hembree et al., 2017, doi:10.1210/jc.2017-01658